Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- COX-2 Inhibitors Show Effects against Cancer
April 2, 2001
- Korosho Urges Generic Makers to Ensure Stable Supply of Their Products
April 2, 2001
- Hp Eradication Saves 320 Bil. in Medical Expenses in 5 Years: Takeda Seminar
April 2, 2001
- BULLETIN
April 2, 2001
- Osteo Genesis Starts Developing Bone Regeneration Technology
April 2, 2001
- BUSINESS NEWS IN BRIEF
April 2, 2001
- MediBIC Licenses Haplotyping Technology from Genaissance
April 2, 2001
- Toho Transfers Business to Affiliated Companies to Increase Efficiency
April 2, 2001
- Sosei, Morphochem to Develop New Telomerase Inhibitor
April 2, 2001
- Industry FTC to Prohibit Financial Support for Social Gatherings at Medical Institutions
April 2, 2001
- Sankyo, Metabasis Agree to Continue Codevelopment of Antidiabetic Drug
April 2, 2001
- Sales of Relenza, Tamiflu Far Below Expectations
April 2, 2001
- Korosho to Start DRG Trial in April
April 2, 2001
- WORLD NEWS IN BRIEF
April 2, 2001
- Most municipal Hospitals Have Anti-Accident Manuals: JMHA Survey
April 2, 2001
- Major Japanese firms Aiming at 20% of Total Sales Overseas in 2005: JPMA Report
April 2, 2001
- MRSA Infections Found in 0.55% of Inpatients: Korosho Survey
April 2, 2001
- Final Draft of Ethical Guidelines for Human Genome Research Approved
April 2, 2001
- Sankyo Ties Up with Menarini to Market CS-866 in Europe
April 2, 2001
- 'Number System' Proposed for Social Security
April 2, 2001
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…